Good news came again from the centralized recruitment and purchase of drugs. Recently, Hubei took the lead in the bid opening of centralized procurement of 19 provincial alliance Chinese patent medicines, with a procurement scale of nearly 10 billion yuan. Finally, 97 enterprises and 111 products were selected, and the average price of the selected products decreased by 42.27% and the maximum decreased by 82.63%. According to the calculation of the annual demand of the 19 provincial alliance, it is estimated that the annual drug cost can be saved by more than 2.6 billion yuan. Since the reform of centralized drug procurement in 2018, no Chinese patent medicine has been included in the scope of large-scale centralized procurement, which is the first centralized procurement bid opening of Chinese patent medicine in China. Previously, the national drug centralized bidding and procurement did not involve Chinese patent medicines, because many Chinese patent medicines were produced exclusively, the formula was confidential, and there was no competition from similar products, so enterprises had the confidence to refuse price. In addition, the quality of many traditional Chinese medicines varies greatly, often from different places of origin, and the prices vary widely, such as saffron, donkey hide gelatin, etc. the popularity of products outside the place of origin has decreased sharply. The quality is affected by many factors such as origin, climate and variety, so the evaluation standard cannot be unified, and the price comparison is more difficult. Nevertheless, there is still much room for centralized bidding and procurement of Chinese patent medicines. Even if there is only one Chinese patent medicine, pharmaceutical enterprises will think that the larger the sales, the better. Volume for price is a common law in the market, and commodities can drive down prices through "group purchase". After the successful negotiation of patent medicine and its inclusion in the medical insurance catalogue, the sales volume will increase greatly. There is no reason for enterprises to miss this opportunity to expand the market. The first centralized collection of Chinese patent medicine has achieved good results, which also proves that this road is feasible. This also shows that medical reform should have the courage and ability to be first. The price of Chinese patent medicine has been rising for many years. In addition to rare Chinese medicinal materials such as Cordyceps sinensis, musk, Angong Niuhuang Pill and donkey hide gelatin, ordinary Chinese medicinal materials also show a rapid price rise trend. Just recently, the prices of Chinese patent medicines of several well-known pharmaceutical enterprises in China have increased by 10% to 20%, including some common varieties. Some Western medicines "can't afford to eat", but the price of some Chinese patent medicines is too high, which is also an urgent problem. Bring Chinese patent medicine into the scope of centralized drug purchase, so as to reverse the price rise momentum of Chinese patent medicine and meet the general expectations of the people. The particularity of Chinese patent medicine has also been fully reflected in the policy. In order to promote the development of traditional Chinese medicine, when canceling the drug addition policy in public hospitals, the state made it clear that "except for decoction pieces of traditional Chinese medicine". At present, in public hospitals, decoction pieces of traditional Chinese medicine can still be added. This is actually a special "welfare" for traditional Chinese medicine, which is conducive to the sale and development of traditional Chinese medicine. Since this preference can be obtained after the successful negotiation of Chinese patent medicine and its smooth entry into the hospital, the centralized recruitment and purchase of Chinese patent medicine has the role of directional distribution of this special "welfare", and the responsibility is greater. In addition, at present, the phenomenon of disorderly competition in Chinese patent medicine is relatively common. Inferior medicines are replaced by good ones, and the quality is uneven, which has become a difficult problem affecting the development of traditional Chinese medicine. Many places have advantageous industries of Chinese patent medicine, but herd action and insufficient cross regional cooperation will also lead to disorderly development and chaos. The industrial layout needs to be guided and standardized. In this context, the centralized recruitment and procurement of Chinese patent medicine can play the role of "baton", which is conducive to the emergence of enterprises with strong strength and pioneering and innovative spirit. It can be seen that the particularity and industrial characteristics of Chinese patent medicine are destined to carry the greater expectations of the society. Compared with the centralized purchase of Western medicine, the centralized purchase of Chinese patent medicine should not only be comprehensively promoted and popularized, but also introduce more detailed rules and explore a more scientific model. While greatly reducing the price of Chinese patent medicine, it should also promote the healthy development of Chinese patent medicine industry and show the strong charm of the treasure of going abroad. (outlook new era)